《大行報告》摩通將永利澳門(01128.HK)納入正面催化劑觀察期
摩根大通發表研究報告指,將永利澳門(01128.HK)納入正面催化劑觀察期,預計集團第三季的盈利表現將優於同行,表現出色。該行認為,強勁的數據應該會推動市場預期,並有助收窄其與歷史水平的估值差距。
該行預計,集團中場的市佔率將顯著增長,料中場賭收按季增長逾20%,而同行則為逾10%。該行料公司的營運開支穩健受控,又對集團在黃金週期間的表現樂觀。該行提到,基於集團所營運的優質資產,其目前9倍EBITDA的估值具有吸引力。此外,該行相信其高負債比率可以在重新評級的情況下釋放大量股權價值,予「增持」評級,目標價11元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.